Corcept Therapeutics - MarketMinute

Corcept Therapeutics

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF (NYSEARCA: XBI) and the Nasdaq Biotechnology Index (NASDAQ: IBB) struggled to find their footing in late March 2026,

Sarepta Therapeutics

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500 and Nasdaq Composite indices tumbled over 1.5% due to lingering inflation concerns and a surprise hawkish

Corcept Therapeutics

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the company’s market capitalization, was triggered by a "perfect storm" of positive regulatory developments and